The company increased its turnover figures and workforce in 2012.

The management team was able to smooth the impact of one time Stock Exchange listing expenses improving net result by 675 k € vs. the submitted original Business Plan.

In a year hit by a serious economic recession, Bionaturis (BNT-MAB) showed consistent growth, improving its results and creating jobs.

 The biotechnology company closed a successful year 2012 marked by important relevant facts like start trading at the Spanish Alternative Stock Market (MAB) in January and the launch in September of a new dermocosmetic business Line (BNT Dermocosmetics). Audited statements show an increase in its sales figures and total income vs. 2011, plus a considerable improvement in yearly net result of 675 k € compared to expectations presented at the Market in January 2012 (DIIM Business Plan).

 As Victor Infante, Bionaturis CEO, mentions, “If I would have to highlight something in 2012 above anything else I would choose our remarkable management capabilities. I refer to being able to smoothen the impact of starting trading in the Stock Market while putting together a new business line. It has been a great piece of a challenge. Our Strategic Plan for Growth has become a tangible reality”.

In its BNT PRODUCTS core business, Bionaturis keeps accomplishing important steps enriching its pipeline and patent portfolio. In this sense, the company has become a reference in oral fish vaccine development for aquaculture as a member of the European Targetfish International consortium and maintains fruitful activities towards licensing at least one vaccine development candidate during the period 2013-2015.

 Regarding its BNT-CDMO business line, the company´s R&D services division, the number of contracts with International corporations and private institutions have increased considerably in line with the pharmaceutical and veterinary industries growing trend of subcontracting alternative manufacturing platforms for biological products, like its proprietary FLYLIFE Technology.

 This way the Andalusian company trading in the Spanish MAB has accomplished its planned objectives, achieving expected targets and position and increasing turnover. Bionaturis is setting the way for a company able to make its vision economically profitable: “A global access to health”.